Affiliation:
1. The Third Affiliated Hospital of Soochow University
2. The Affiliated Sir Run Run Hospital of Nanjing Medical University
Abstract
Abstract
Background: Prostate cancer (PCa) is one of the common malignant tumors and it is difficult to diagnose at its early stage. MiR-183-5p has been reported involved in the proliferation of human PCa, this study aimed to investigate how miR-183-5p affects the migration and invasion of prostate cancer.
Methods: In this study, we analyzed the expression of miR-183-5p in PCa patients and its correlation with clinicopathological parameters based on TCGA data portal. CCK-8, migration assay and invasion and wound-healing assay were performed to detect proliferation, migration and invasion in PCa cells.
Results:We found the expression of miR-183-5p was significantly increased in PCa tissues, and high expression of miR-183 was positively associated with poor prognosis of PCa patients. Over-expression of miR-183-5p promoted the migration, invasion capacities of PCa cells, whereas knockdown of miR-183-5p showed reversed function. Furthermore, luciferase reporter assay showed TET1 was identified as a direct target of miR-183-5p, which was negatively correlation with miR-183-5p expression level. Importantly, rescue experiments demonstrated TET1 over-expression could reverse miR-183-5p mimic induced-acceleration of PCa malignant progression.
Conclusion:Our results indicated that miR-183-5p could act as a tumor promoter in PCa and it accelerated the malignant progression of PCa by directly targeting and down-regulating TET1.
Publisher
Research Square Platform LLC
Reference43 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;Cancer J Clin,2018
2. Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis;Birnbaum MD;Oncogene,2019
3. Pan J, Zhao J, Ni X, Gan H, Wei Y, Wu J, Zhang T, Wang Q, Stephen JF, Wang B et al. The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancer.Molecular oncology2022.
4. ESTAT3 Inhibitor AG-490 Inhibits the Growth of Prostate Cancer by miR-503-5p Both In Vivo and In Vitro;Tan G;Technol Cancer Res Treat,2020
5. LncRNA MCM3AP-AS1 Promotes Cell Proliferation and Invasion Through Regulating miR-543-3p/SLC39A10/PTEN Axis in Prostate Cancer;Jia Z;OncoTargets and therapy,2020